Guangzhou Hanfang Launches MultiAdaptable Injectable Soybean Oil for Global Pharma

Domestically Produced, Globally Compliant Injectable Excipient Meets High-End Formulation Needs

Guangzhou, China – 2026 – Guangzhou Hanfang Pharmaceutical Company Limited, a leading provider of high-end pharmaceutical excipients and active pharmaceutical ingredients (APIs), today announces the launch of its multi-adaptable injectable soybean oil. This domestically developed product is engineered to address the core pain point of unstable supply of high-quality injectable excipients for global pharmaceutical manufacturers, featuring strict quality control, global compliance certifications, and customizable specifications. The launch strengthens Hanfang’s position in the global injectable excipient market and expands its product portfolio to better serve clients across over 20 countries and regions.

Core Product Advantages and Technical Highlights

As an energy supplement and pharmaceutical excipient, Hanfang’s injectable soybean oil is designed for high-end injectable formulation manufacturers. Its multi-adaptable nature supports a wide range of injection production needs, providing a reliable alternative to imported products that have long dominated the market. The product leverages the company’s integrated green production technologies, such as supercritical CO₂ extraction and membrane separation, ensuring high purity and stable performance throughout the production and storage process.

Global Compliance and Certifications

To meet global market access requirements, the injectable soybean oil complies with international standards and holds key certifications including EU CEP, US FDA US-DMF, Mexico Cofepris, and India DCGI. These credentials enable the product to enter major markets across Europe, North America, Asia-Pacific, and beyond, ensuring regulatory compliance for pharmaceutical clients worldwide.

Availability and Customization Services

The multi-adaptable injectable soybean oil is now available for pre-order through Guangzhou Hanfang’s official website and global authorized distributors, with immediate mass production and global shipment underway. In addition to standard specifications, the company offers customized services tailored to specific formulation requirements, helping clients optimize their production processes and meet unique market demands.

Executive Quote

"The launch of our multi-adaptable injectable soybean oil marks a key step in our strategy to provide reliable, domestically produced high-end pharmaceutical excipients globally," said Xu Wendong, General Manager, Deputy Director of National Engineering Research Center at Guangzhou Hanfang Pharmaceutical Company Limited. "This product not only addresses supply chain vulnerabilities for pharmaceutical manufacturers but also demonstrates our commitment to technological innovation and self-reliance in the biopharmaceutical industry."

Industry Context and Strategic Alignment

According to Grand View Research, the global pharmaceutical excipients market is projected to reach $88.5 billion by 2026, driven by growing demand for high-end injectable formulations and increasing focus on supply chain resilience. Guangzhou Hanfang’s new injectable soybean oil aligns with this industry trend, offering a cost-effective, compliant solution that supports global pharmaceutical manufacturers’ operational stability.

Future Plans

Looking ahead, Guangzhou Hanfang Pharmaceutical Company Limited will continue to focus on high-end pharmaceutical lipid excipients, increasing R&D investment to develop more innovative products. The company will also expand its global sales and service network to provide localized support for clients in more regions, enhancing its global market presence.

About Guangzhou Hanfang Pharmaceutical Company Limited

Established in 1998, Guangzhou Hanfang Pharmaceutical Company Limited is a core state-owned enterprise under Guangzhou Pharmaceutical Holdings Group, specializing in high-end pharmaceutical lipid excipients, oncology APIs, and Ganoderma health products. Headquartered in Guangzhou, China, the company operates a sole production base in Conghua District, with R&D centers in Haizhu District and Zhuhai Hengqin. With over 240 patents, international certifications, and a client base of more than 1,000 including B. Braun and AstraZeneca, Hanfang is dedicated to driving technological self-reliance, breaking "bottleneck" technologies, and safeguarding pharmaceutical supply chain security. For more information, visit http://byshanhanfang.com/